Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on November 20, 2018. The report details a material definitive agreement entered into on the same date between the Company and John M. Desmarais, a director and principal stockholder, regarding the restructuring of debt and equity instruments.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial metrics disclosed relate to the restructuring of the following obligations:
- Promissory Note 1: Principal amount of $175,000 held by John M. Desmarais.
- Promissory Note 2: Principal amount of $500,000 held by a trust for the benefit of Mr. Desmarais' immediate family.
- Total Debt Restructured: $675,000 in principal amounts.
- Warrant Adjustment: Exercise price reduction for 844,444 shares from $4.00 to $1.50 per share.
Material Changes Versus Prior Period
The filing reports a material change in the terms of existing financial instruments rather than a change in operational performance compared to a prior period. The specific changes include:
- Debt Maturity Extension: The due date for both promissory notes was extended from December 1, 2018, to December 31, 2019.
- Warrant Terms Modification: The expiration date of warrants held by Mr. Desmarais was extended from December 31, 2018, to December 31, 2019.
- Exercise Price Reduction: The exercise price for the aforementioned warrants was reduced by 62.5% (from $4.00 to $1.50).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general business risks. The transaction indicates a liquidity management strategy where the Company secured an extension of debt obligations from a principal stockholder in exchange for more favorable equity terms (lower exercise price and extended duration) for that stockholder.
Key Facts for Investor Verification
- Verify the total outstanding debt and liquidity position of the Company to assess the significance of the $675,000 extension.
- Confirm the dilution impact of the 844,444 warrants with the reduced exercise price of $1.50.
- Review the relationship between the Company and John M. Desmarais to understand the terms of the related-party transaction.
- Check subsequent filings to determine if the Company met the new December 31, 2019, repayment deadline.